奥昔卡因
|
|
|
- CAS号:
- 126-27-2
- 英文名:
- Oxethazaine
- 英文别名:
- fh099;C12552;mutesa;oxaine;Wy 806;tepilta;mucaine;mucoxin;muthesa;betalgil
- 中文名:
- 奥昔卡因
- 中文别名:
- 羟乙卡因;奥西卡因;阿塞赛因;奥昔卡因;2-双(N-甲基-N-苯基叔丁基-氨基甲酰甲基)氨基乙醇;2-羟乙基亚氨基双(N-[Α,Α-二甲基苯乙基]-N-甲基乙酰胺)
- CBNumber:
- CB0287425
- 分子式:
- C28H41N3O3
- 分子量:
- 467.64
- MOL File:
- 126-27-2.mol
|
|
|
奥昔卡因化学性质
-
熔点:
-
104-105°C
-
|
-
沸点:
-
570.1°C (rough estimate)
-
|
-
密度:
-
1.0974 (rough estimate)
-
|
-
折射率:
-
1.7800 (estimate)
-
|
-
储存条件:
-
Refrigerator
-
|
-
溶解度:
-
Practically insoluble in water; freely soluble in methanol; soluble in ethyl acetate.
-
|
-
酸度系数(pKa):
-
14.62±0.10(Predicted)
-
|
-
颜色:
-
White to Off-White
-
|
-
水溶解性:
-
<0.1 g/100 mL at 23 ºC
-
|
-
CAS 数据库:
-
126-27-2(CAS DataBase Reference)
-
|
-
EPA化学物质信息:
-
Oxethazaine (126-27-2)
-
|
奥昔卡因性质、用途与生产工艺
Oxethazaine (Oxetacaine) 是芬特明的酸性前体，是一种具有耐酸性和口服活性的镇痛试剂。Oxethazaine (Oxetacaine) 具有缓解消化性溃疡疾病或食管炎引起的疼痛的潜力。
Oxetacaine (intraperitoneal injection; 5, 10, and 15 mg/kg; during days 4–11) doses induces significant conditioned place preference (CPP), and there are no differences among the groups. While its postive control group phentermine only 3 mg/kg causes significant CPP..
|
Animal Model:
|
Male Wistar rats
|
|
Dosage:
|
5, 10, and 15 mg/kg; during days 4–11
|
|
Administration:
|
Intraperitoneal injection
|
|
Result:
|
Showed a significant CPP in vivo.
|
奥昔卡因
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/04/30 | HY-B0955 | 奥昔卡因
Oxethazaine | 126-27-2 | 50mg | 400元 |
| 2024/04/30 | HY-B0955 | Oxethazaine | | 100 mg | 600元 |
奥昔卡因
生产厂家
全球有 90家供应商
奥昔卡因国内生产厂家
126-27-2, 奥昔卡因 相关搜索:
- Amines
- Pharmaceuticals
- Intermediates & Fine Chemicals
- Aromatics
- VIRAMUNE
- 药靶配体
- 小分子抑制剂
- Alphabetic
- Analytical Chromatography Product Catalog
- Analytical Standards
- C28H41N3O3
- 2-羟乙基亚氨基双(N-[Α,Α-二甲基苯乙基]-N-甲基乙酰胺)
- 奥昔卡因
- 2-双(N-甲基-N-苯基叔丁基-氨基甲酰甲基)氨基乙醇
- 羟乙卡因
- 奥西卡因
- 阿塞赛因
- 126-27-2
- Clopamide Impurity 2 (Clopamide EP Impurity B)
- peptic ulcer disease,hemorrhoid,Inhibitor,esophagitis,HBV,analgesic,Oxethazaine,inhibit,precursor,Hepatitis B virus
- OxetacaineQ: What is
Oxetacaine Q: What is the CAS Number of
Oxetacaine Q: What is the storage condition of
Oxetacaine Q: What are the applications of
Oxetacaine
- Oxethazaine API - BP
- Wy 806
- Storocaine
- Storocain
- 2,2'-[(2-Hydroxyethyl)iMino]bis[N-(α,α-diMethylphenethyl)-N-MethylacetaMide]
- oxethacaina
- oxaine
- n,n-bis(n-methyl-n-phenyl-tert-butylacetamido)-beta-hydroxyethylamine
- muthesa
- mutesa
- mucoxin
- mucaine
- N,N-bis(alpha,alpha-dimethylphenethyl)-N,N-dimethyl-2,2-(2-hydroxyethylimino)di(acetamide)
- 2-di(n-methyl-n-phenyl-tert-butyl-carbamoylmethyl)aminoethanol
- 2-HYDROXYETHYLIMINOBIS-[N-(ALPHA,ALPHA-DIMETHYLPHENETHYL)-N-METHYLACETAMIDE]
- topicain
- tepilta
- stomacain
- oxethacaine
- fh099
- betalgil
- acetamide,2,2’-(2-hydroxyethyl)imino)bis(n-(1,1-dimethylphenylethyl)-n-methy
- 2,2’-((2-hydroxyethyl)imino)bis(n-(alpha,alpha-dimethylphenethyl)-n-methylac
- 2,2’-((2-hydroxyethyl)imino)bis(n-(alpha,alpha-dimethylphenethyl)-n-acetamid
- 2,2’-((2-hydroxyethyl)imino)bis(n-(1,1-dimethyl-2-phenylethyl)-n-methylaceta
- C12552
- Acetamide, 2,2'-[(2-hydroxyethyl)imino]bis[N-(1,1-dimethyl-2-phenylethyl)-N-methyl-
- 2,2'-[(2-Hydroxyethyl)imino]bis[N-(a,a-dimethylphenethyl)-N-methylacetamide]
- 2-hydroxyethyliminobis(n-[α,α-dimethylphenethyl]-n-methylacetamide)
- OXETACAINE
- OXETHAZINE
- OXETHAZAINE